| MicroRNA silencing for cancer therapy targeted to the tumour microenvironment CJ Cheng, R Bahal, IA Babar, Z Pincus, F Barrera, C Liu, A Svoronos, ... Nature 518 (7537), 107-110, 2015 | 890 | 2015 |
| Antisense oligonucleotides: an emerging area in drug discovery and development K Dhuri, C Bechtold, E Quijano, H Pham, A Gupta, A Vikram, R Bahal Journal of clinical medicine 9 (6), 2004, 2020 | 438 | 2020 |
| The growth of siRNA-based therapeutics: Updated clinical studies MM Zhang, R Bahal, TP Rasmussen, JE Manautou, X Zhong Biochemical pharmacology 189, 114432, 2021 | 427 | 2021 |
| Synthesis and Characterization of Conformationally Preorganized, (R)-Diethylene Glycol-Containing γ-Peptide Nucleic Acids with Superior Hybridization Properties … B Sahu, I Sacui, S Rapireddy, KJ Zanotti, R Bahal, BA Armitage, DH Ly The Journal of organic chemistry 76 (14), 5614-5627, 2011 | 230 | 2011 |
| Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy A Wahane, A Waghmode, A Kapphahn, K Dhuri, A Gupta, R Bahal Molecules 25 (12), 2866, 2020 | 190 | 2020 |
| In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery R Bahal, N Ali McNeer, E Quijano, Y Liu, P Sulkowski, A Turchick, YC Lu, ... Nature communications 7 (1), 13304, 2016 | 176 | 2016 |
| Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium NA McNeer, K Anandalingam, RJ Fields, C Caputo, S Kopic, A Gupta, ... Nature communications 6 (1), 6952, 2015 | 158 | 2015 |
| In utero nanoparticle delivery for site-specific genome editing AS Ricciardi, R Bahal, JS Farrelly, E Quijano, AH Bianchi, VL Luks, ... Nature communications 9 (1), 2481, 2018 | 156 | 2018 |
| Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response M Sahraei, B Chaube, Y Liu, J Sun, A Kaplan, NL Price, W Ding, ... The Journal of clinical investigation 129 (12), 5518-5536, 2019 | 115 | 2019 |
| Focus: genome editing: therapeutic peptide nucleic acids: principles, limitations, and opportunities E Quijano, R Bahal, A Ricciardi, WM Saltzman, PM Glazer The Yale journal of biology and medicine 90 (4), 583, 2017 | 110 | 2017 |
| Sequence-unrestricted, Watson-Crick recognition of double helical B-DNA by (R)-MiniPEG-γPNAs R Bahal, B Sahu, S Rapireddy, CM Lee, DH Ly Chembiochem: a European journal of chemical biology 13 (1), 56, 2011 | 110 | 2011 |
| Strand invasion of extended, mixed-sequence B-DNA by γPNAs G He, S Rapireddy, R Bahal, B Sahu, DH Ly Journal of the American Chemical Society 131 (34), 12088-12090, 2009 | 107 | 2009 |
| Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma YE Seo, HW Suh, R Bahal, A Josowitz, J Zhang, E Song, J Cui, ... Biomaterials 201, 87-98, 2019 | 95 | 2019 |
| Nanotechnology for delivery of peptide nucleic acids (PNAs) A Gupta, R Bahal, M Gupta, PM Glazer, WM Saltzman Journal of Controlled Release 240, 302-311, 2016 | 73 | 2016 |
| Absorption, distribution, metabolism, and excretion of US Food and Drug Administration–Approved antisense oligonucleotide drugs JM Migliorati, S Liu, A Liu, A Gogate, S Nair, R Bahal, TP Rasmussen, ... Drug Metabolism and Disposition 50 (6), 888-897, 2022 | 71 | 2022 |
| Anti-tumor activity of miniPEG-γ-modified PNAs to inhibit microRNA-210 for cancer therapy A Gupta, E Quijano, Y Liu, R Bahal, SE Scanlon, E Song, WC Hsieh, ... Molecular Therapy-Nucleic Acids 9, 111-119, 2017 | 70 | 2017 |
| Adverse drug reactions and toxicity of the food and drug administration–approved antisense oligonucleotide drugs F Alhamadani, K Zhang, R Parikh, H Wu, TP Rasmussen, R Bahal, ... Drug Metabolism and Disposition 50 (6), 879-887, 2022 | 67 | 2022 |
| Strand invasion of mixed-sequence, double-helical B-DNA by γ-peptide nucleic acids containing G-clamp nucleobases under physiological conditions S Rapireddy, R Bahal, DH Ly Biochemistry 50 (19), 3913-3918, 2011 | 66 | 2011 |
| Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis NL Price, V Miguel, W Ding, AK Singh, S Malik, N Rotllan, A Moshnikova, ... JCI insight 4 (22), 2019 | 64 | 2019 |
| Single-stranded γPNAs for in vivo site-specific genome editing via Watson-Crick recognition R Bahal, E Quijano, N A McNeer, Y Liu, D C Bhunia, F Lopez-Giraldez, ... Current gene therapy 14 (5), 331-342, 2014 | 53 | 2014 |
